Clinical Trial Update: Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study evaluating bosutinib combined with inotuzumab ozogamicin in CD22-positive ALL and CML showed completed status with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia with Bcr-abl1
• Blast Phase Chronic Myelogenous Leukemia Bcr-abl1-positive
• Chronic Myeloid Leukemia Bcr-abl1 Positive
• Myelogenous Leukemia Bcr-abl1 Positive
• Myelogenous Leukemia Philadelphia Chromosome Positive Bcr-abl1 Positive

Drugs mentioned

• Bosutinib (bosutinib)
• Inotuzumab ozogamicin (inotuzumab ozogamicin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-07-17